APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Pain Drugs

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Selected research

Industry Growth & Trends

Global Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032

2 January 2026128 pages

Choose your research edition.

Industry ResearchOsteoarthritis Pain Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Osteoarthritis Pain Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Osteoarthritis Pain Drugs market size, estimates, and forecasts are presented in terms of sales volume (M Dose) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Osteoarthritis Pain Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Osteoarthritis Pain Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Osteoarthritis Pain Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Osteoarthritis Pain Drugs Market by Company

Pfizer

Bayer

SK Chemicals

GSK

Sanofi

Crystal Genomics

Johnson & Johnson

Sino Biopharmaceutical

Haohai Biological

Zhejiang Chengyi Pharmaceutical

Freda

Bright Future

Jingfeng Pharmaceutical

Chugai Pharmaceutical

Mikasa Seiyaku

Taisho Pharmaceutical

Seikagaku Corporation

GlaxoSmithKline

Eli Lilly

Novartis

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Osteoarthritis Pain Drugs Segment by Type

Oral

Injection

External

Osteoarthritis Pain Drugs Segment by Application

Medical Care

Personal Care

Osteoarthritis Pain Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Pain Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Pain Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Pain Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Osteoarthritis Pain Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Osteoarthritis Pain Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Table 2. Major Company of Injection Table 3. Major Company of External Table 4. Global Osteoarthritis Pain Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 6. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Osteoarthritis Pain Drugs Price by Type (2021-2026) & (US$/Dose) Table 10. Global Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 11. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Osteoarthritis Pain Drugs Price by Type (2027-2032) & (US$/Dose) Table 15. North America Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 16. North America Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 18. Europe Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 20. Asia-Pacific Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 22. Latin America Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 24. Middle East and Africa Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Osteoarthritis Pain Drugs Industry Trends Table 26. Osteoarthritis Pain Drugs Industry Drivers Table 27. Osteoarthritis Pain Drugs Industry Opportunities and Challenges Table 28. Osteoarthritis Pain Drugs Industry Restraints Table 29. Global Osteoarthritis Pain Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Osteoarthritis Pain Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Osteoarthritis Pain Drugs Sales by Company (2021-2026) & (M Dose) Table 32. Global Osteoarthritis Pain Drugs Sales Share by Company (2021-2026) Table 33. Global Osteoarthritis Pain Drugs Market Price by Company (2021-2026) & (US$/Dose) Table 34. Global Osteoarthritis Pain Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Osteoarthritis Pain Drugs Major Company Production Sites and Headquarters Table 36. Global Osteoarthritis Pain Drugs Company, Product Type & Application Table 37. Global Osteoarthritis Pain Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Osteoarthritis Pain Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Osteoarthritis Pain Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (M Dose) Table 42. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 46. Global Osteoarthritis Pain Drugs Sales by Region (2027-2032) & (M Dose) Table 47. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Osteoarthritis Pain Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2027-2032) Table 51. Global Osteoarthritis Pain Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 53. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Osteoarthritis Pain Drugs Price by Application (2021-2026) & (US$/Dose) Table 57. Global Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 58. Global Osteoarthritis Pain Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Osteoarthritis Pain Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Osteoarthritis Pain Drugs Price by Application (2027-2032) & (US$/Dose) Table 62. North America Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 63. North America Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 65. Europe Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 67. Asia-Pacific Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 69. Latin America Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 71. Middle East and Africa Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 75. Pfizer Osteoarthritis Pain Drugs Product Portfolio Table 76. Pfizer Recent Development Table 77. Bayer Company Information Table 78. Bayer Business Overview Table 79. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 80. Bayer Osteoarthritis Pain Drugs Product Portfolio Table 81. Bayer Recent Development Table 82. SK Chemicals Company Information Table 83. SK Chemicals Business Overview Table 84. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 85. SK Chemicals Osteoarthritis Pain Drugs Product Portfolio Table 86. SK Chemicals Recent Development Table 87. GSK Company Information Table 88. GSK Business Overview Table 89. GSK Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 90. GSK Osteoarthritis Pain Drugs Product Portfolio Table 91. GSK Recent Development Table 92. Sanofi Company Information Table 93. Sanofi Business Overview Table 94. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 95. Sanofi Osteoarthritis Pain Drugs Product Portfolio Table 96. Sanofi Recent Development Table 97. Crystal Genomics Company Information Table 98. Crystal Genomics Business Overview Table 99. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 100. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio Table 101. Crystal Genomics Recent Development Table 102. Johnson & Johnson Company Information Table 103. Johnson & Johnson Business Overview Table 104. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 105. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio Table 106. Johnson & Johnson Recent Development Table 107. Sino Biopharmaceutical Company Information Table 108. Sino Biopharmaceutical Business Overview Table 109. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 110. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 111. Sino Biopharmaceutical Recent Development Table 112. Haohai Biological Company Information Table 113. Haohai Biological Business Overview Table 114. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 115. Haohai Biological Osteoarthritis Pain Drugs Product Portfolio Table 116. Haohai Biological Recent Development Table 117. Zhejiang Chengyi Pharmaceutical Company Information Table 118. Zhejiang Chengyi Pharmaceutical Business Overview Table 119. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 120. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 121. Zhejiang Chengyi Pharmaceutical Recent Development Table 122. Freda Company Information Table 123. Freda Business Overview Table 124. Freda Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 125. Freda Osteoarthritis Pain Drugs Product Portfolio Table 126. Freda Recent Development Table 127. Bright Future Company Information Table 128. Bright Future Business Overview Table 129. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 130. Bright Future Osteoarthritis Pain Drugs Product Portfolio Table 131. Bright Future Recent Development Table 132. Jingfeng Pharmaceutical Company Information Table 133. Jingfeng Pharmaceutical Business Overview Table 134. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 135. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 136. Jingfeng Pharmaceutical Recent Development Table 137. Chugai Pharmaceutical Company Information Table 138. Chugai Pharmaceutical Business Overview Table 139. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 140. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 141. Chugai Pharmaceutical Recent Development Table 142. Mikasa Seiyaku Company Information Table 143. Mikasa Seiyaku Business Overview Table 144. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 145. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio Table 146. Mikasa Seiyaku Recent Development Table 147. Taisho Pharmaceutical Company Information Table 148. Taisho Pharmaceutical Business Overview Table 149. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 150. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 151. Taisho Pharmaceutical Recent Development Table 152. Seikagaku Corporation Company Information Table 153. Seikagaku Corporation Business Overview Table 154. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 155. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio Table 156. Seikagaku Corporation Recent Development Table 157. GlaxoSmithKline Company Information Table 158. GlaxoSmithKline Business Overview Table 159. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 160. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio Table 161. GlaxoSmithKline Recent Development Table 162. Eli Lilly Company Information Table 163. Eli Lilly Business Overview Table 164. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 165. Eli Lilly Osteoarthritis Pain Drugs Product Portfolio Table 166. Eli Lilly Recent Development Table 167. Novartis Company Information Table 168. Novartis Business Overview Table 169. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 170. Novartis Osteoarthritis Pain Drugs Product Portfolio Table 171. Novartis Recent Development Table 172. Horizon Pharma Company Information Table 173. Horizon Pharma Business Overview Table 174. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 175. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio Table 176. Horizon Pharma Recent Development Table 177. Abbott Company Information Table 178. Abbott Business Overview Table 179. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 180. Abbott Osteoarthritis Pain Drugs Product Portfolio Table 181. Abbott Recent Development Table 182. Mylan Company Information Table 183. Mylan Business Overview Table 184. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 185. Mylan Osteoarthritis Pain Drugs Product Portfolio Table 186. Mylan Recent Development Table 187. Daiichi Sankyo Company Information Table 188. Daiichi Sankyo Business Overview Table 189. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 190. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio Table 191. Daiichi Sankyo Recent Development Table 192. TEVA Company Information Table 193. TEVA Business Overview Table 194. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 195. TEVA Osteoarthritis Pain Drugs Product Portfolio Table 196. TEVA Recent Development Table 197. Almatica Pharma Company Information Table 198. Almatica Pharma Business Overview Table 199. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 200. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio Table 201. Almatica Pharma Recent Development Table 202. Astellas Pharma Company Information Table 203. Astellas Pharma Business Overview Table 204. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 205. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio Table 206. Astellas Pharma Recent Development Table 207. Tide Pharmaceutical Company Information Table 208. Tide Pharmaceutical Business Overview Table 209. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 210. Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 211. Tide Pharmaceutical Recent Development Table 212. Iroko Pharmaceuticals Company Information Table 213. Iroko Pharmaceuticals Business Overview Table 214. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 215. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio Table 216. Iroko Pharmaceuticals Recent Development Table 217. Hengrui Pharmaceutical Company Information Table 218. Hengrui Pharmaceutical Business Overview Table 219. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 220. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 221. Hengrui Pharmaceutical Recent Development Table 222. North America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (M Dose): 2021 VS 2025 VS 2032 Table 223. North America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 224. North America Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 225. North America Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032) & (M Dose) Table 226. North America Osteoarthritis Pain Drugs Sales Market Share Forecast by Country (2027-2032) Table 227. North America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 228. North America Osteoarthritis Pain Drugs Market Size by Country (2021-2026) & (US$ Million) Table 229. North America Osteoarthritis Pain Drugs Market Share by Country (2021-2026) Table 230. North America Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 231. North America Osteoarthritis Pain Drugs Market Share Forecast by Country (2027-2032) Table 232. Europe Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (M Dose): 2021 VS 2025 VS 2032 Table 233. Europe Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 234. Europe Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 235. Europe Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032) & (M Dose) Table 236. Europe Osteoarthritis Pain Drugs Sales Market Share Forecast by Country (2027-2032) Table 237. Europe Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 238. Europe Osteoarthritis Pain Drugs Market Size by Country (2021-2026) & (US$ Million) Table 239. Europe Osteoarthritis Pain Drugs Market Share by Country (2021-2026) Table 240. Europe Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 241. Europe Osteoarthritis Pain Drugs Market Share Forecast by Country (2027-2032) Table 242. Asia-Pacific Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (M Dose): 2021 VS 2025 VS 2032 Table 243. Asia-Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 244. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 245. Asia-Pacific Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032) & (M Dose) Table 246. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share Forecast by Country (2027-2032) Table 247. Asia-Pacific Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 248. Asia-Pacific Osteoarthritis Pain Drugs Market Size by Country (2021-2026) & (US$ Million) Table 249. Asia-Pacific Osteoarthritis Pain Drugs Market Share by Country (2021-2026) Table 250. Asia-Pacific Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 251. Asia-Pacific Osteoarthritis Pain Drugs Market Share Forecast by Country (2027-2032) Table 252. Latin America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (M Dose): 2021 VS 2025 VS 2032 Table 253. Latin America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 254. Latin America Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 255. Latin America Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032) & (M Dose) Table 256. Latin America Osteoarthritis Pain Drugs Sales Market Share Forecast by Country (2027-2032) Table 257. Latin America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 258. Latin America Osteoarthritis Pain Drugs Market Size by Country (2021-2026) & (US$ Million) Table 259. Latin America Osteoarthritis Pain Drugs Market Share by Country (2021-2026) Table 260. Latin America Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 261. Latin America Osteoarthritis Pain Drugs Market Share Forecast by Country (2027-2032) Table 262. Middle East and Africa Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (M Dose): 2021 VS 2025 VS 2032 Table 263. Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 264. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 265. Middle East and Africa Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032) & (M Dose) Table 266. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share Forecast by Country (2027-2032) Table 267. Middle East and Africa Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 268. Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country (2021-2026) & (US$ Million) Table 269. Middle East and Africa Osteoarthritis Pain Drugs Market Share by Country (2021-2026) Table 270. Middle East and Africa Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 271. Middle East and Africa Osteoarthritis Pain Drugs Market Share Forecast by Country (2027-2032) Table 272. Key Raw Materials Table 273. Raw Materials Key Suppliers Table 274. Osteoarthritis Pain Drugs Distributors List Table 275. Osteoarthritis Pain Drugs Customers List Table 276. Research Programs/Design for This Report Table 277. Authors List of This Report Table 278. Secondary Sources Table 279. Primary Sources List of Figures Figure 1. Osteoarthritis Pain Drugs Image Figure 2. Global Osteoarthritis Pain Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoarthritis Pain Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Osteoarthritis Pain Drugs Sales (2021-2032) & (M Dose) Figure 5. Oral Image Figure 6. Global Oral Sales YoY Growth (2021-2032) & (M Dose) Figure 7. Injection Image Figure 8. Global Injection Sales YoY Growth (2021-2032) & (M Dose) Figure 9. External Image Figure 10. Global External Sales YoY Growth (2021-2032) & (M Dose) Figure 11. Global Osteoarthritis Pain Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Osteoarthritis Pain Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Osteoarthritis Pain Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Osteoarthritis Pain Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Osteoarthritis Pain Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Osteoarthritis Pain Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Osteoarthritis Pain Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Osteoarthritis Pain Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Osteoarthritis Pain Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Medical Care Image Figure 26. Global Medical Care Sales YoY Growth (2021-2032) & (M Dose) Figure 27. Personal Care Image Figure 28. Global Personal Care Sales YoY Growth (2021-2032) & (M Dose) Figure 29. Global Osteoarthritis Pain Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Osteoarthritis Pain Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Osteoarthritis Pain Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Osteoarthritis Pain Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Osteoarthritis Pain Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Osteoarthritis Pain Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Osteoarthritis Pain Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Osteoarthritis Pain Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Osteoarthritis Pain Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Figure 42. North America Osteoarthritis Pain Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Osteoarthritis Pain Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Figure 46. Europe Osteoarthritis Pain Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Osteoarthritis Pain Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Figure 50. Asia-Pacific Osteoarthritis Pain Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Osteoarthritis Pain Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Figure 54. Latin America Osteoarthritis Pain Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Osteoarthritis Pain Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Figure 58. Middle East and Africa Osteoarthritis Pain Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Osteoarthritis Pain Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Osteoarthritis Pain Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Osteoarthritis Pain Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Bayer
  • SK Chemicals
  • GSK
  • Sanofi
  • Crystal Genomics
  • Johnson & Johnson
  • Sino Biopharmaceutical
  • Haohai Biological
  • Zhejiang Chengyi Pharmaceutical
  • Freda
  • Bright Future
  • Jingfeng Pharmaceutical
  • Chugai Pharmaceutical
  • Mikasa Seiyaku
  • Taisho Pharmaceutical
  • Seikagaku Corporation
  • GlaxoSmithKline
  • Eli Lilly
  • Novartis
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Osteoarthritis Pain Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Osteoarthritis Pain Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Osteoarthritis Pain Drugs Market by Type
  6. 1.3.1 Oral
  7. 1.3.2 Injection
  8. 1.3.3 External
  9. 1.4 Global Osteoarthritis Pain Drugs Market Size by Type
  10. 1.4.1 Global Osteoarthritis Pain Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Osteoarthritis Pain Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Osteoarthritis Pain Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Osteoarthritis Pain Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Osteoarthritis Pain Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Osteoarthritis Pain Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Osteoarthritis Pain Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Osteoarthritis Pain Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Osteoarthritis Pain Drugs Industry Trends
  2. 2.2 Osteoarthritis Pain Drugs Industry Drivers
  3. 2.3 Osteoarthritis Pain Drugs Industry Opportunities and Challenges
  4. 2.4 Osteoarthritis Pain Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Osteoarthritis Pain Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Osteoarthritis Pain Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Osteoarthritis Pain Drugs Price (2021-2026)
  4. 3.4 Global Osteoarthritis Pain Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Osteoarthritis Pain Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Osteoarthritis Pain Drugs Company, Product Type & Application
  7. 3.7 Global Osteoarthritis Pain Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Osteoarthritis Pain Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Osteoarthritis Pain Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Osteoarthritis Pain Drugs Tier 1, Tier 2, and Tier 3
4 Osteoarthritis Pain Drugs Regional Status and Outlook
  1. 4.1 Global Osteoarthritis Pain Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Osteoarthritis Pain Drugs Historic Market Size by Region
  3. 4.2.1 Global Osteoarthritis Pain Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Osteoarthritis Pain Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Osteoarthritis Pain Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Osteoarthritis Pain Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Osteoarthritis Pain Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Osteoarthritis Pain Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Osteoarthritis Pain Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Osteoarthritis Pain Drugs by Application
  1. 5.1 Osteoarthritis Pain Drugs Market by Application
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Osteoarthritis Pain Drugs Market Size by Application
  5. 5.2.1 Global Osteoarthritis Pain Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Osteoarthritis Pain Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Osteoarthritis Pain Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Osteoarthritis Pain Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Osteoarthritis Pain Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Osteoarthritis Pain Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Osteoarthritis Pain Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Osteoarthritis Pain Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 SK Chemicals
  14. 6.3.1 SK Chemicals Company Information
  15. 6.3.2 SK Chemicals Business Overview
  16. 6.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
  18. 6.3.5 SK Chemicals Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Crystal Genomics
  32. 6.6.1 Crystal Genomics Company Information
  33. 6.6.2 Crystal Genomics Business Overview
  34. 6.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
  36. 6.6.5 Crystal Genomics Recent Developments
  37. 6.7 Johnson & Johnson
  38. 6.7.1 Johnson & Johnson Company Information
  39. 6.7.2 Johnson & Johnson Business Overview
  40. 6.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
  42. 6.7.5 Johnson & Johnson Recent Developments
  43. 6.8 Sino Biopharmaceutical
  44. 6.8.1 Sino Biopharmaceutical Company Information
  45. 6.8.2 Sino Biopharmaceutical Business Overview
  46. 6.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  48. 6.8.5 Sino Biopharmaceutical Recent Developments
  49. 6.9 Haohai Biological
  50. 6.9.1 Haohai Biological Company Information
  51. 6.9.2 Haohai Biological Business Overview
  52. 6.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
  54. 6.9.5 Haohai Biological Recent Developments
  55. 6.10 Zhejiang Chengyi Pharmaceutical
  56. 6.10.1 Zhejiang Chengyi Pharmaceutical Company Information
  57. 6.10.2 Zhejiang Chengyi Pharmaceutical Business Overview
  58. 6.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  60. 6.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments
  61. 6.11 Freda
  62. 6.11.1 Freda Company Information
  63. 6.11.2 Freda Business Overview
  64. 6.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
  66. 6.11.5 Freda Recent Developments
  67. 6.12 Bright Future
  68. 6.12.1 Bright Future Company Information
  69. 6.12.2 Bright Future Business Overview
  70. 6.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
  72. 6.12.5 Bright Future Recent Developments
  73. 6.13 Jingfeng Pharmaceutical
  74. 6.13.1 Jingfeng Pharmaceutical Company Information
  75. 6.13.2 Jingfeng Pharmaceutical Business Overview
  76. 6.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  78. 6.13.5 Jingfeng Pharmaceutical Recent Developments
  79. 6.14 Chugai Pharmaceutical
  80. 6.14.1 Chugai Pharmaceutical Company Information
  81. 6.14.2 Chugai Pharmaceutical Business Overview
  82. 6.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  84. 6.14.5 Chugai Pharmaceutical Recent Developments
  85. 6.15 Mikasa Seiyaku
  86. 6.15.1 Mikasa Seiyaku Company Information
  87. 6.15.2 Mikasa Seiyaku Business Overview
  88. 6.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
  90. 6.15.5 Mikasa Seiyaku Recent Developments
  91. 6.16 Taisho Pharmaceutical
  92. 6.16.1 Taisho Pharmaceutical Company Information
  93. 6.16.2 Taisho Pharmaceutical Business Overview
  94. 6.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  96. 6.16.5 Taisho Pharmaceutical Recent Developments
  97. 6.17 Seikagaku Corporation
  98. 6.17.1 Seikagaku Corporation Company Information
  99. 6.17.2 Seikagaku Corporation Business Overview
  100. 6.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
  102. 6.17.5 Seikagaku Corporation Recent Developments
  103. 6.18 GlaxoSmithKline
  104. 6.18.1 GlaxoSmithKline Company Information
  105. 6.18.2 GlaxoSmithKline Business Overview
  106. 6.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
  108. 6.18.5 GlaxoSmithKline Recent Developments
  109. 6.19 Eli Lilly
  110. 6.19.1 Eli Lilly Company Information
  111. 6.19.2 Eli Lilly Business Overview
  112. 6.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
  114. 6.19.5 Eli Lilly Recent Developments
  115. 6.20 Novartis
  116. 6.20.1 Novartis Company Information
  117. 6.20.2 Novartis Business Overview
  118. 6.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
  120. 6.20.5 Novartis Recent Developments
  121. 6.21 Horizon Pharma
  122. 6.21.1 Horizon Pharma Company Information
  123. 6.21.2 Horizon Pharma Business Overview
  124. 6.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
  126. 6.21.5 Horizon Pharma Recent Developments
  127. 6.22 Abbott
  128. 6.22.1 Abbott Company Information
  129. 6.22.2 Abbott Business Overview
  130. 6.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
  132. 6.22.5 Abbott Recent Developments
  133. 6.23 Mylan
  134. 6.23.1 Mylan Company Information
  135. 6.23.2 Mylan Business Overview
  136. 6.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
  138. 6.23.5 Mylan Recent Developments
  139. 6.24 Daiichi Sankyo
  140. 6.24.1 Daiichi Sankyo Company Information
  141. 6.24.2 Daiichi Sankyo Business Overview
  142. 6.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
  144. 6.24.5 Daiichi Sankyo Recent Developments
  145. 6.25 TEVA
  146. 6.25.1 TEVA Company Information
  147. 6.25.2 TEVA Business Overview
  148. 6.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
  150. 6.25.5 TEVA Recent Developments
  151. 6.26 Almatica Pharma
  152. 6.26.1 Almatica Pharma Company Information
  153. 6.26.2 Almatica Pharma Business Overview
  154. 6.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
  156. 6.26.5 Almatica Pharma Recent Developments
  157. 6.27 Astellas Pharma
  158. 6.27.1 Astellas Pharma Company Information
  159. 6.27.2 Astellas Pharma Business Overview
  160. 6.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
  162. 6.27.5 Astellas Pharma Recent Developments
  163. 6.28 Tide Pharmaceutical
  164. 6.28.1 Tide Pharmaceutical Company Information
  165. 6.28.2 Tide Pharmaceutical Business Overview
  166. 6.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  168. 6.28.5 Tide Pharmaceutical Recent Developments
  169. 6.29 Iroko Pharmaceuticals
  170. 6.29.1 Iroko Pharmaceuticals Company Information
  171. 6.29.2 Iroko Pharmaceuticals Business Overview
  172. 6.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
  174. 6.29.5 Iroko Pharmaceuticals Recent Developments
  175. 6.30 Hengrui Pharmaceutical
  176. 6.30.1 Hengrui Pharmaceutical Company Information
  177. 6.30.2 Hengrui Pharmaceutical Business Overview
  178. 6.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  180. 6.30.5 Hengrui Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Osteoarthritis Pain Drugs Sales by Country
  2. 7.1.1 North America Osteoarthritis Pain Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Osteoarthritis Pain Drugs Market Size by Country
  6. 7.2.1 North America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Osteoarthritis Pain Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Osteoarthritis Pain Drugs Sales by Country
  2. 8.1.1 Europe Osteoarthritis Pain Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Osteoarthritis Pain Drugs Market Size by Country
  6. 8.2.1 Europe Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Osteoarthritis Pain Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Osteoarthritis Pain Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Osteoarthritis Pain Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Osteoarthritis Pain Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Osteoarthritis Pain Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Osteoarthritis Pain Drugs Sales by Country
  2. 10.1.1 South America Osteoarthritis Pain Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Osteoarthritis Pain Drugs Market Size by Country
  6. 10.2.1 South America Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Osteoarthritis Pain Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Osteoarthritis Pain Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Osteoarthritis Pain Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Osteoarthritis Pain Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Osteoarthritis Pain Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Osteoarthritis Pain Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Osteoarthritis Pain Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Osteoarthritis Pain Drugs Value Chain Analysis
  2. 12.1.1 Osteoarthritis Pain Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Osteoarthritis Pain Drugs Production Mode & Process
  7. 12.2 Osteoarthritis Pain Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Osteoarthritis Pain Drugs Distributors
  10. 12.2.3 Osteoarthritis Pain Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst